Astraveus' miniaturized, high capacity, end-to-end microfluidic platform will enable the flexibility to manufacture both current and future CGT products, while also setting new benchmarks in improved efficiency and consistency of processing. I am proud to support Astraveus and their team as they continue to revolutionize this field.

Tara Clark

Expert in Cell and Gene Therapy Commercialization, Strategic Advisor to Astraveus